Table 2

Logistic regression analysis of risk of toxicity in patients receiving immune checkpoint inhibitors

All-grade toxicity≥G3 toxicity
UnivariateMultivariableUnivariateMultivariable
Age category
<65 years1.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
65–74 years1.14 (0.73 to 1.76)1.27 (0.79 to 2.03)0.825 (0.47 to 1.45)0.96 (0.51 to 1.81)
≥75 years0.88 (0.54 to 1.42)1.15 (0.70 to 1.91)0.53 (0.26 to 1.07)0.73 (0.33 to 1.61)
Primary site
Melanoma1.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
NSCLC0.79 (0.51 to 1.24)0.95 (0.59 to 1.53)0.50 (0.26 to 0.96)0.79 (0.38 to 1.62)
RCC1.02 (0.60 to 1.74)1.50 (0.86 to 2.61)0.41 (0.18 to 0.95)0.90 (0.36 to 2.22)
Treatment type
PD-1 inhibitor1.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
Ipilimumab+nivolumab4.72 (1.36 to 16.39)5.24 (1.48 to 18.50)17.94 (6.71 to 47.91)16.41 (5.88 to 45.84)
Ipilimumab8.17 (3.18 to 20.96)8.93 (3.43 to 23.29)7.73 (4.08 to 14.65)7.02 (3.53 to 13.96)
  • OR with 95% CI for toxicity using logistic regression.

  • NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.